Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1746–1751. doi: 10.1038/sj.bjc.6690278

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

W Kuhn 1, B Schmalfeldt 1, U Reuning 1, L Pache 1, U Berger 3, K Ulm 3, N Harbeck 1, K Späthe 1, P Dettmar 2, H Höfler 2, F Jänicke 4, M Schmitt 1, H Graeff 1
PMCID: PMC2362775  PMID: 10206287

Abstract

Strong evidence has accumulated on the prognostic value of tumour-associated proteolytic factors in patients afflicted with solid malignant tumours, including advanced ovarian cancer. We evaluated the prognostic impact of the protease urokinase plasminogen activator (uPA) and its inhibitor PAI-1 on overall survival in patients with advanced ovarian cancer stage FIGO IIIc in order to select patients at risk. uPA and PAI-1 antigen were determined by ELISA in primary tumour tissue extracts of 86 ovarian cancer patients FIGO stage IIIc enrolled in a prospective study. Univariate and multivariate analyses were performed using the Cox proportional hazard model. The time-varying coefficient model of Gray was used to assess the time-dependent strength of prognostic factors tumour mass, uPA and PAI-1 on overall survival. In all patients, uPA and PAI-1 (optimized cut-offs of 2.0 and 27.5 ng mg−1 protein respectively), in addition to the traditional prognostic parameters of residual tumour mass, nodal status, grading and ascites volume, were of prognostic significance in univariate analysis for overall survival. Even in patients with residual tumour mass (n = 43), the statistically independent prognostic impact of PAI-1 persisted, allowing further discrimination between low- and high-risk patients. In multivariate analysis, residual tumour mass (P < 0.001, relative risk (RR) 4.5), PAI-1 (P < 0.001; RR 3.1) and nodal status (P = 0.022, RR 2.6) turned out to be strong, statistically independent prognostic parameters. Evaluation of the time-dependent prognostic impact of residual tumour mass and PAI-1 on overall survival (n = 86, 50 months) revealed that the prognostic power of these factors increased with time. In patients with advanced ovarian cancer, both residual tumour mass and PAI-1 are statistically independent strong prognostic factors. Even within patient subgroups with or without residual tumour mass, PAI-1 allowed selection of patients at risk who might benefit from individualized therapy protocols. © 1999 Cancer Research Campaign

Keywords: prognostic factors, ovarian cancer

Full Text

The Full Text of this article is available as a PDF (119.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Astedt B., Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature. 1976 Jun 17;261(5561):595–597. doi: 10.1038/261595a0. [DOI] [PubMed] [Google Scholar]
  2. Barbareschi M., Gasparini G., Morelli L., Forti S., Dalla Palma P. Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat. 1995;36(2):181–192. doi: 10.1007/BF00666039. [DOI] [PubMed] [Google Scholar]
  3. Benedetti-Panici P., Greggi S., Scambia G., Salerno M. G., Baiocchi G., Laurelli G., Menichella G., Pierelli L., Foddai M. L., Serafini R. Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer. 1995 Nov;31A(12):1987–1992. doi: 10.1016/0959-8049(95)00337-1. [DOI] [PubMed] [Google Scholar]
  4. Berchuck A., Rodriguez G. C., Kamel A., Dodge R. K., Soper J. T., Clarke-Pearson D. L., Bast R. C., Jr Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 1991 Feb;164(2):669–674. doi: 10.1016/s0002-9378(11)80044-x. [DOI] [PubMed] [Google Scholar]
  5. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol. 1990 Aug;38(2):203–209. doi: 10.1016/0090-8258(90)90042-j. [DOI] [PubMed] [Google Scholar]
  6. Burghardt E., Girardi F., Lahousen M., Tamussino K., Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991 Feb;40(2):103–106. doi: 10.1016/0090-8258(91)90099-q. [DOI] [PubMed] [Google Scholar]
  7. Casslén B., Bossmar T., Lecander I., Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer. 1994;30A(9):1302–1309. doi: 10.1016/0959-8049(94)90178-3. [DOI] [PubMed] [Google Scholar]
  8. Conese M., Blasi F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe Seyler. 1995 Mar;376(3):143–155. [PubMed] [Google Scholar]
  9. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  10. Dettmar P., Harbeck N., Thomssen C., Pache L., Ziffer P., Fizi K., Jänicke F., Nathrath W., Schmitt M., Graeff H. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer. 1997;75(10):1525–1533. doi: 10.1038/bjc.1997.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Duffy M. J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J. J., Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990 Nov 1;50(21):6827–6829. [PubMed] [Google Scholar]
  12. Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Bontenbal M., Jänicke F., Klijn J. G. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992 Nov 1;52(21):6101–6105. [PubMed] [Google Scholar]
  13. Friedlander M. L., Quinn M. A., Fortune D., Foo M. S., Toppila M., Hudson C. N., Russell P. The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors. Gynecol Oncol. 1989 Feb;32(2):184–190. doi: 10.1016/s0090-8258(89)80031-9. [DOI] [PubMed] [Google Scholar]
  14. Griffiths C. T., Parker L. M., Fuller A. F., Jr Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979 Feb;63(2):235–240. [PubMed] [Google Scholar]
  15. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
  16. Heintz A. P., Hacker N. F., Berek J. S., Rose T. P., Munoz A. K., Lagasse L. D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986 Jun;67(6):783–788. doi: 10.1097/00006250-198606000-00007. [DOI] [PubMed] [Google Scholar]
  17. Hofmann R., Lehmer A., Buresch M., Hartung R., Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer. 1996 Aug 1;78(3):487–492. doi: 10.1002/(SICI)1097-0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  18. Jänicke F., Hölscher M., Kuhn W., von Hugo R., Pache L., Siewert J. R., Graeff H. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 1992 Oct 15;70(8):2129–2136. doi: 10.1002/1097-0142(19921015)70:8<2129::aid-cncr2820700820>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  19. Jänicke F., Schmitt M., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet. 1989 Oct 28;2(8670):1049–1049. doi: 10.1016/s0140-6736(89)91070-2. [DOI] [PubMed] [Google Scholar]
  20. Kaern J., Tropé C. G., Kristensen G. B., Pettersen E. O. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer. 1994 Apr 1;73(7):1870–1877. doi: 10.1002/1097-0142(19940401)73:7<1870::aid-cncr2820730716>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  21. Kanse S. M., Kost C., Wilhelm O. G., Andreasen P. A., Preissner K. T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996 May 1;224(2):344–353. doi: 10.1006/excr.1996.0144. [DOI] [PubMed] [Google Scholar]
  22. Kigawa J., Minagawa Y., Ishihara H., Kanamori Y., Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer. 1993 Aug 1;72(3):804–808. doi: 10.1002/1097-0142(19930801)72:3<804::aid-cncr2820720328>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  23. Kobayashi H., Fujishiro S., Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994 Dec 15;54(24):6539–6548. [PubMed] [Google Scholar]
  24. Kuhn W., Jänicke F., Pache L., Hölscher M., Schattenmann G., Schmalfeldt B., Anderl H., Schüle G., Dettmar P., Siewert J. R. Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtshilfe Frauenheilkd. 1993 May;53(5):293–302. doi: 10.1055/s-2007-1022886. [DOI] [PubMed] [Google Scholar]
  25. Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Jänicke F., Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401–409. doi: 10.1006/gyno.1994.1313. [DOI] [PubMed] [Google Scholar]
  26. Lage J. M., Weinberg D. S., Huettner P. C., Mark S. D. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage. Cancer. 1992 Jun 1;69(11):2668–2675. doi: 10.1002/1097-0142(19920601)69:11<2668::aid-cncr2820691108>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  27. Liu G., Shuman M. A., Cohen R. L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995 Feb 8;60(4):501–506. doi: 10.1002/ijc.2910600413. [DOI] [PubMed] [Google Scholar]
  28. Makar A. P., Baekelandt M., Tropé C. G., Kristensen G. B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995 Feb;56(2):175–180. doi: 10.1006/gyno.1995.1027. [DOI] [PubMed] [Google Scholar]
  29. Merkel D. E., McGuire W. L. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer. 1990 Mar 1;65(5):1194–1205. doi: 10.1002/1097-0142(19900301)65:5<1194::aid-cncr2820650528>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  30. Nekarda H., Siewert J. R., Schmitt M., Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet. 1994 Jan 8;343(8889):117–117. doi: 10.1016/s0140-6736(94)90845-1. [DOI] [PubMed] [Google Scholar]
  31. Pedersen N., Schmitt M., Rønne E., Nicoletti M. I., Høyer-Hansen G., Conese M., Giavazzi R., Dano K., Kuhn W., Jänicke F. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest. 1993 Nov;92(5):2160–2167. doi: 10.1172/JCI116817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pujade-Lauraine E., Lu H., Mirshahi S., Soria J., Soria C., Bernadou A., Kruithof E. K., Lijnen H. R., Burtin P. The plasminogen-activation system in ovarian tumors. Int J Cancer. 1993 Aug 19;55(1):27–31. doi: 10.1002/ijc.2910550106. [DOI] [PubMed] [Google Scholar]
  33. Roldan A. L., Cubellis M. V., Masucci M. T., Behrendt N., Lund L. R., Danø K., Appella E., Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990 Feb;9(2):467–474. doi: 10.1002/j.1460-2075.1990.tb08132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Scarabelli C., Gallo A., Zarrelli A., Visentin C., Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol. 1995 Mar;56(3):328–337. doi: 10.1006/gyno.1995.1059. [DOI] [PubMed] [Google Scholar]
  35. Schmalfeldt B., Kuhn W., Reuning U., Pache L., Dettmar P., Schmitt M., Jänicke F., Höfler H., Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995 Sep 15;55(18):3958–3963. [PubMed] [Google Scholar]
  36. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F., Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997 Jul;78(1):285–296. [PubMed] [Google Scholar]
  37. Schmitt M., Thomssen C., Ulm K., Seiderer A., Harbeck N., Höfler H., Jänicke F., Graeff H. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer. 1997;76(3):306–311. doi: 10.1038/bjc.1997.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sier C. F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., Frigerio L., Ferrari A., Danø K., Brünner N. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998 May 1;58(9):1843–1849. [PubMed] [Google Scholar]
  39. Sier C. F., Vloedgraven H. J., Ganesh S., Griffioen G., Quax P. H., Verheijen J. H., Dooijewaard G., Welvaart K., van de Velde C. J., Lamers C. B. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology. 1994 Nov;107(5):1449–1456. doi: 10.1016/0016-5085(94)90549-5. [DOI] [PubMed] [Google Scholar]
  40. Stefansson S., Lawrence D. A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996 Oct 3;383(6599):441–443. doi: 10.1038/383441a0. [DOI] [PubMed] [Google Scholar]
  41. Tyson F. L., Boyer C. M., Kaufman R., O'Briant K., Cram G., Crews J. R., Soper J. T., Daly L., Fowler W. C., Jr, Haskill J. S. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol. 1991 Sep;165(3):640–646. doi: 10.1016/0002-9378(91)90300-g. [DOI] [PubMed] [Google Scholar]
  42. Wei Y., Lukashev M., Simon D. I., Bodary S. C., Rosenberg S., Doyle M. V., Chapman H. A. Regulation of integrin function by the urokinase receptor. Science. 1996 Sep 13;273(5281):1551–1555. doi: 10.1126/science.273.5281.1551. [DOI] [PubMed] [Google Scholar]
  43. van der Burg M. E., Henzen-Logmans S. C., Berns E. M., van Putten W. L., Klijn J. G., Foekens J. A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer. 1996 Dec 20;69(6):475–479. doi: 10.1002/(SICI)1097-0215(19961220)69:6<475::AID-IJC10>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  44. van der Burg M. E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., Lacave A. J., Nardi M., Renard J., Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995 Mar 9;332(10):629–634. doi: 10.1056/NEJM199503093321002. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES